Patrizia Cavazzoni

Patrizia Cavazzoni is the director of the U.S. Food and Drug Administration's (FDA) Center for Drug Evaluation and Research (CDER). Prior to this position she worked at Pfizer and had been a psychiatrist

Patrizia Cavazzoni
Official FDA Portrait
Director of the Center for Drug Evaluation and Research[1]
Assumed office
April 12, 2021
Acting: May 2020 – April 2021
Preceded byJanet Woodcock
Acting Principal Deputy Commissioner of Food and Drugs[2]
In office
January 2019 – February 2019
Succeeded byAmy Abernethy
Deputy Center Director for Operations of the FDA Center for Drug Evaluation and Research
In office
January 2018 – May 2020
Personal details
EducationMcGill University (MD)[2]

Education

Cavazzoni earned her medical degree from McGill University and subsequently was a fellow at the University of Ottawa.[2] She then joined the University of Ottawa as an assistant professor before moving to the pharmaceutical industry,[3] where she worked at Pfizer.[4]

She moved to the U.S. Food and Drug Administration in 2018, and was named acting director of the U.S. Food and Drug Administration's (FDA) Center for Drug Evaluation and Research in 2020[5][6] and director in 2021.[4] During the COVID-19 pandemic, Cavazzoni has spoken publicly about the need for science to guide policies[7] and about the future of the Center for Drug Evaluation and Research after the COVID-19 pandemic.[8] She also noted that she would hand Donald Trump a blank sheet of paper if asked to submit a list of workers who should not receive due process protections.[9]

Research

While she worked at the Royal Ottawa Hospital, Cavazzoni examined the link between genetics and personality, and the chemicals implicated in brain chemistry.[10] She further examined the connections between diabetes and patients receiving antipsychotic medications.[11]

Selected publications
  • Buse, John B.; Cavazzoni, Patrizia; Hornbuckle, Kenneth; Hutchins, David; Breier, Alan; Jovanovic, Lois (2003-02-01). "A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the United States". Journal of Clinical Epidemiology. 56 (2): 164–170. doi:10.1016/S0895-4356(02)00588-7. ISSN 0895-4356. PMID 12654411.
  • Breier, Alan; Berg, Paul H.; Thakore, Jogin H.; Naber, Dieter; Gattaz, Wagner F.; Cavazzoni, Patrizia; Walker, Daniel J.; Roychowdhury, Suraja M.; Kane, John M. (2005-10-01). "Olanzapine Versus Ziprasidone: Results of a 28-Week Double-Blind Study in Patients With Schizophrenia". American Journal of Psychiatry. 162 (10): 1879–1887. doi:10.1176/appi.ajp.162.10.1879. ISSN 0002-953X. PMID 16199834.
  • Cavazzoni, P (2003). "Nizatidine for prevention of weight gain with olanzapine: a double-blind placebo-controlled trial". European Neuropsychopharmacology. 13 (2): 81–85. doi:10.1016/S0924-977X(02)00127-X. PMID 12650950. S2CID 43289579.

Honors and awards

Cavazzoni received the American College of Psychiatrists's Laughlin Fellowship.[2]

References
  1. "CDER Leadership Bios". U.S. Food and Drug Administration. April 12, 2021.
  2. "Patrizia Cavazzoni M.D." U.S. Food and Drug Administration. April 12, 2021.
  3. "Patricia Cavazzoni". NIH HEAL Initiative. 2019-09-22. Retrieved 2022-03-30.
  4. Oakes, Kari (April 21, 2021). "Cavazzoni named to permanent CDER director role". www.raps.org. Retrieved 2022-03-30.
  5. Florko, Nicholas (June 23, 2020). "The new Janet: The FDA turns to a quiet problem-solver who brings expertise - and a little controversy". STAT; Boston – via ProQuest.
  6. Florko, Nicholas (May 22, 2020). "FDA shuffles longtime division head, Janet Woodcock, to focus exclusively on Covid-19 vaccine project". STAT; Boston – via ProQuest.
  7. Zeller, Patrizia Cavazzoni, Peter Marks, Susan Mayne, Judy McMeekin, Jeff Shuren, Steven Solomon, Janet Woodcock and Mitch (10 September 2020). "Senior FDA career executives: We're following the science to protect public health in pandemic". USA TODAY. Retrieved 2022-03-30.{{cite web}}: CS1 maint: multiple names: authors list (link)
  8. Oakes, Kari (21 May 2021). "Cavazzoni paints CDER's post-pandemic future". www.raps.org. Retrieved 2022-03-30.
  9. Hohmann, James (November 3, 2020). "Analysis | The Daily 202: Election pits Trump vs. the experts". Washington Post. ISSN 0190-8286. Retrieved 2022-03-30.
  10. Sibbald, Barbara (30 May 1999). "Busting the happiness barrier: Scientists are searching for common ground to make us happier". The Ottawa Citizen. pp. C3 – via ProQuest.
  11. Cavazzoni, Patrizia; Mukhopadhyay, Nitai; Carlson, Christopher; Breier, Alan; Buse, John (2004). "Retrospective analysis of risk factors in patients with treatment-emergent diabetes during clinical trials of antipsychotic medications". British Journal of Psychiatry. 184 (S47): s94–s101. doi:10.1192/bjp.184.47.s94. ISSN 0007-1250. PMID 15056601. S2CID 15936219.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.